Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Meizhou
Clinical trial register · China

Clinical Trials in Meizhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19282 matching records held by the registry are in this view. Synced 15 Nov 2026, 03:17 UTC
19282
Studies in scope
all four open statuses
11840
Recruiting now
open to new participants
2032
Lead sponsors
across recruiting studies
Top sites
Beijing 5606 Shanghai 3892 Guangzhou 3359 Hangzhou 1833 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Nanfang Hospital, Southern Medical University4 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3 Shanghai Junshi Bioscience Co., Ltd.2 Guangzhou Lupeng Pharmaceutical Company LTD.2 BeOne Medicines2 Guangdong Provincial People's Hospital2 Seagen, a wholly owned subsidiary of Pfizer2 Peking Union Medical College Hospital2 MediLink Therapeutics (Suzhou) Co., Ltd.2 Lifetech Scientific (Shenzhen) Co., Ltd.1 Guangzhou Patronus Biotech Co., Ltd.1 ArriVent BioPharma, Inc.1 Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd1 Takeda1 Zhuliling1 Shanghai Henlius Biotech1 BeiGene1 Shanghai MicroPort Medical (Group) Co., Ltd.1 EMD Serono Research & Development Institute, Inc.1 Yonghong Li1 Beijing Tiantan Hospital1 Xiang Gao1 Alpha Biopharma (Jiangsu) Co., Ltd.1 First Affiliated Hospital of Shantou University Medical College1 Show all 32
Site location
Beijing5606 Shanghai3892 Guangzhou3359 Hangzhou1833 Wuhan1342 Chengdu1310 Nanjing1216 Changsha1159 Chongqing1085 Fuzhou1041 Tianjin940 Zhengzhou926 Hefei909 Jinan794 Changchun642 Shenzhen585 Harbin549 Nanchang449 Nanning443 Xi'an443 Suzhou433 Shenyang406 Xiamen391 Shijiazhuang351 Lanzhou273 Show all 625
All 625 locations
Target enrolment
to

Trials with a site in Meizhou

46 of 19282 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
300
Guangzhou, Meizhou, Wuhan, Changsha, Chengdu, Tianjin
2026-09-12
Not yet open
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
NCT07466251Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque
DrugRecaticimab
Peking Union Medical College Hospital
Phase 4
1,212
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2026-09-01
Recruiting
Ausper Biopharma Co., Ltd.
Phase 2
320
Beijing, Chongqing, Xiamen, Guangzhou, Jiangmen, Meizhou, Qingyuan, Shenzhen
2026-06-05
Recruiting
Shanghai Henlius Biotech
Phase 1
258
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou
2026-05-25
Recruiting
RemeGen Co., Ltd.
Phase 2/3
80
Beijing, Chongqing, Fuzhou, Meizhou, Nanjing, Shijiazhuang, Zhengzhou, Wuhan
2026-05-12
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Beijing, Guangzhou, Meizhou, Nanning, Hong Kong, Wuhan, Nanjing, Nanchang
2026-05-06
Recruiting
Yonghong Li
Phase 2
109
Guangzhou, Meizhou
2026-04-16
Not yet open
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
142
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2026-03
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
86
Beijing, Fuzhou, Meizhou, Shanghai, Chengdu
2026-01-22
Active, closed
DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction
NCT07761390Breast Neoplasms, Breast Reconstruction, Postoperative Complications
Zhuliling
Observational
1,500
Xiamen, Dongguan, Guangzhou, Huizhou, Meizhou, Shantou, Shanwei, Shaoguan
2026-01-01
Recruiting
Alpha Biopharma (Jiangsu) Co., Ltd.
Observational
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Meizhou
2025-12-29
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
560
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Guangzhou, Meizhou, Shantou
2025-12-24
Recruiting
Guangdong Association of Clinical Trials
Phase 2
120
Guangzhou, Meizhou, Shantou, Shenzhen
2025-12-15
Recruiting
Pfizer
Phase 3
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-12-11
Recruiting
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
150
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Nanning, Shijiazhuang
2025-11-27
Recruiting
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
300
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Meizhou, Shaoguan, Shenzhen
2025-11-10
Recruiting
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
NCT06902740Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
300
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2025-11-07
Recruiting
Shanghai QuietD Biotechnology Co., Ltd.
Phase 2
120
Meizhou, Luoyang, Nanyang, Changchun, Meihekou, Benxi, Fuxin, Shengyang
2025-10-14
Recruiting
Guangdong Provincial People's Hospital
Not applicable
96
Beijing, Longyan, Zhangzhou, Guangzhou, Meizhou, Shantou, Shaoguan, Zhongshan
2025-09-08
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Not yet open
Nanfang Hospital, Southern Medical University
Not applicable
110
Guangzhou, Huizhou, Jieyang, Meizhou
2025-09-01
Recruiting
Nanfang Hospital, Southern Medical University
Observational
264
Guangzhou, Huizhou, Jieyang, Meizhou
2025-09
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
72
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Meizhou, Shantou, Nanning
2025-07-30
Recruiting
A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography
NCT07133516Artificial Intelligence (AI), Artificial Intelligence (AI) in Diagnosis, Cardiovascular Diseases (CVD), Echocardiography
First Hospital of China Medical University
Observational
1,600
Huainan, Fuzhou, Meizhou, Shantou, Shenzhen, Baise City, Guilin, Liuzhou
2025-07-22
Not yet open
Nanfang Hospital, Southern Medical University
Observational
338
Guangzhou, Huizhou, Meizhou
2025-07-20
Active, closed
BeOne Medicines
Phase 3
153
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shenzhen, Nanning
2025-05-29
Recruiting
Guangzhou Patronus Biotech Co., Ltd.
Phase 1
92
Meizhou
2025-03-13
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
170
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Meizhou, Qingyuan, Nanning
2025-03-13
Recruiting
BeOne Medicines
Phase 1
695
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-01-10
Recruiting
Accuracy of LAA Occluder Size Selection: CT vs. DSA During Combined AF Ablation and LAA Occlusion
NCT06455644Atrial Fibrillation, Arrhythmias, Cardiac, Heart Diseases, Cardiovascular Diseases
First Affiliated Hospital of Shantou University Medical College
Not applicable
238
Foshan, Meizhou, Shantou, Zhongshan
2024-07
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
420
Hefei, Fuzhou, Lanzhou, Guangzhou, Huizhou, Jiangmen, Meizhou, Guigang
2024-07
Recruiting
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
NCT06307314Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker
Nanfang Hospital, Southern Medical University
Observational
300
Guangzhou, Fuzhou, Huizhou, Jieyang, Meizhou
2024-02-01
Recruiting
Beijing Tiantan Hospital
Phase 3
1,380
Beijing, Chongqing, Qianjiang, Guangzhou, Heyuan, Maoming, Meizhou, Yunfu
2024-01-11
Recruiting
Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease
NCT06780683Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
DrugUpadacitinib
Xiang Gao
Observational
174
Guangzhou, Meizhou, Shenzhen, Liuzhou, Nanning
2024-01-01
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
DrugYL202 should be infused
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Recruiting
Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.
NCT05774288Patent Foramen Ovale, Cryptogenic Stroke
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
244
Beijing, Guangzhou, Meizhou, Changsha, Changchun, Shenyang, Jinan, Kunming
2023-06-08
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Beijing, Meizhou, Xuhui, Hangzhou, Cangzhou, Shushan, Zhengzhou, Changchun
2023-06-01
Recruiting
Post-market European & Asian Registry to Evaluate the Minos™ Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment
NCT07674173Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm Using Endovascular Stent Graft
Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd
Observational
200
Lanzhou, Meizhou, Shenzhen, Changsha, Xiangtan, Yueyang, Zibo, Binhai
2023-03-05
Active, closed
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
62
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2023-02-21
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Fuzhou, Lanzhou, Guangzhou, Meizhou, Haikou, Chengde, Tangshan, Harbin
2022-10-24
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
133
Chizhou, Fuzhou, Wuwei, Guangzhou, Meizhou, Shijiazhuang, Wuhan, Harbin
2022-07-26
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Hefei, Guangzhou, Meizhou, Liuzhou, Nanning, Haikou, Baoding, Zhengzhou
2022-03-07
Active, closed
Shanghai MicroPort Medical (Group) Co., Ltd.
Not applicable
200
Meizhou
2022-02-28
Recruiting
Guangdong Provincial People's Hospital
Observational
90,000
Foshan, Guangzhou, Meizhou, Qingyuan, Zhuhai, Ganzhou
2021-12-27
Recruiting
BeiGene
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Meizhou, Hechi
2018-09-19
Active, closed
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
NCT03221036Moderately to Severely Active Ulcerative Colitis
DrugVedolizumab
Takeda
Phase 3
392
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Meizhou
2017-08-03
Rows per page Showing 1–46 of 46
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-china/city/meizhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,282 studies in total at the last sync on 15 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 46 of those studies with a site in Meizhou.

How many clinical trials are recruiting in Meizhou?

33 of the 46 studies on this page are recruiting new participants as of the 15 Nov 2026, 03:17 UTC sync. A further 5 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Meizhou), 46 studies
PhaseStudiesRecruitingShare
Phase 312626.1%
Observational9719.6%
Phase 29819.6%
Not applicable5310.9%
Phase 15410.9%
Phase 1/2336.5%
Phase 4214.3%
Phase 2/3112.2%

Most active sponsors

Lead sponsors with the most studies (Meizhou)
Lead sponsorStudiesRecruiting
Nanfang Hospital, Southern Medical University42
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.32
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.32
BeOne Medicines21
Guangdong Provincial People's Hospital22
Guangzhou Lupeng Pharmaceutical Company LTD.21
MediLink Therapeutics (Suzhou) Co., Ltd.22
Peking Union Medical College Hospital21
Seagen, a wholly owned subsidiary of Pfizer21
Shanghai Junshi Bioscience Co., Ltd.21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.